© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dexrazoxane Hydrochloride, a compound known in the chemical world for its cardioprotective action in cancer therapy, stands out thanks to its robust molecular structure. The material has made its mark especially in situations involving anthracycline chemotherapy drugs, offering an important safeguard for heart tissue. Factoring in the chemical’s safety features and the risks it can introduce when mishandled, full understanding of its composition, structure, and handling requirements stays crucial across pharmaceutical settings and manufacturing environments. Having worked with hazardous chemicals in research labs, I have seen strict inventory control and safety audits focus on such substances for good reason.
Known chemically as C11H16N4O4•HCl, Dexrazoxane Hydrochloride appears structurally as a derivative of ethylenediaminetetraacetic acid, locked into a unique ring structure. The molecular weight lands at 312.27 g/mol for the base compound, with hydrochloride increasing the total. Its configuration, built around dual imide groups and complex nitrogen bonds, lets it chelate metal ions effectively, producing the medical effects valued in oncology spheres.
In its raw form, Dexrazoxane Hydrochloride appears as a crystalline powder, with variations sometimes encountered as loose flakes or, rarely, as compact pearls. The solid phase changes little at room temperature, though exposure to moisture or direct sunlight alters surface quality and clumping. Most users recognize it instantly by its white to off-white appearance and near-odorless quality. The density comes in at about 1.41 g/cm³, based on typical lab dehydration data. Laboratories often prepare Dexrazoxane Hydrochloride as a solution before use. It dissolves well in water, especially under gentle warming, forming a clear, colorless liquid that stays stable under controlled refrigeration. I have prepared such solutions, always noting that dust control and solution clarity correlate with final product safety in injection-grade batches.
Quality assurance in batch manufacturing pushes for high specification standards. Pharmaceutical grade products routinely show purity rates above 98%, with loss on drying not exceeding 2.0%. Residual solvents, checked by gas chromatography, hold under strict international limits, with particular attention to methanol or other toxic traces. Melting point readings sit between 194°C and 198°C, serving as a reference point for material identity. Particle size distribution affects handling during bulk transfers, so modern factories run sieve analyses to prevent airborne contamination.
Trade and transportation hinge on accurate customs codes. The Harmonized System (HS) assigns Dexrazoxane Hydrochloride to code 2932299090, falling under heterocyclic compounds with nitrogen hetero-atom(s), excluding other specified groups. Following international law, importers and exporters declare this code for customs and regulatory compliance in pharmaceutical trade and raw material distribution.
Chemicals with medical power such as Dexrazoxane Hydrochloride come bundled with health precautions. Material safety data sheets flag acute inhalation and skin contact risks, meaning gloves, lab coats, and ventilation controls form the backbone of safe practice. Exposure hazards make training non-negotiable, especially with powdered solids and freshly prepared liquid solutions. Long-term or repeated exposure increases risks that include cellular toxicity, with animal data showing organ load with sub-chronic ingestion. Waste requires segregating in accordance with hazardous chemical rules, a detail that environmental officers reinforce on every audit. Disposal practices often mirror those for cytotoxic drugs, far from the waste lines of regular pharmaceuticals.
Dexrazoxane Hydrochloride comes into its own in specialty drug manufacturing and research applications. It serves as an intermediate or protective agent, especially in assembling doxorubicin or daunorubicin cancer therapies. Its role as a raw material remains critically tied to purity, since trace impurities or incorrect forms can break sterility or trigger adverse reactions in sensitive patients. In the broader industrial context, suppliers of pharmaceutical raw materials treat Dexrazoxane Hydrochloride storage as high-priority, tracking stocks by batch, expiry, and contaminant screening.
This material stores best in cool, dry spaces, sealed in airtight packs and shielded from sunlight. Stable for over two years under these conditions, Dexrazoxane Hydrochloride shows little decomposition at ambient temperatures. I have seen expiry dates enforced strictly, with periodic retesting in lots that approach shelf-life boundaries. Solution preparation should happen as close as possible to application time, because reactivity with common solvents and oxygenate breakdown stay possible risks.
Working with specialty chemicals like Dexrazoxane Hydrochloride highlights the link between chemical knowledge and practical safety. From my experience in pharmaceutical manufacturing and quality control, mishandling even a small batch can disrupt entire drug runs or, worse, place operators at medical risk. This compound, with its detailed regulations, safety requirements, and chemical specificity, shows exactly why technical training and vigilance never become redundant. Industry-wide, solutions include routine training updates, investment in modern containment, and open reporting of near-misses so that real-world experience keeps refining best practices day in and day out.
